Pandemic Pricing: The Risks and Rewards of Fast-Tracking Value-Based Drug Evaluations

Matt Sussman, VP of Modeling & Strategy at Panalgo, discusses the risks and rewards of fast-tracking drug price evaluations in the COVID era in this Pharmacy Times article. He notes that ICER’s expedited evaluation of remdesivir raises some questions related to value-based pricing evaluations that shouldn’t be overlooked. Read the full article for Sussman’s view on the risks of rushing and the rewards of readiness when it comes to value-based pricing in the COVID era.